Intrinsic molecular (homozygous Mlh1 and constitutional Msh2 knockout) and immunological differences (baseline immune status, degree of immune suppression) may best explain these findings and are consistent with the heterogeneous clinical responses in individual cancer patients [30]. This evidence concerns the gene MSH2 and cancer.